THL Partners Acquires Celerion for $1.8B in Major Life Sciences Deal
THL Partners is acquiring a majority stake in Celerion for $1.8 billion from H.I.G. Capital.
Why it matters: The deal emphasizes robust private equity interest in healthcare and advances for legal teams handling life sciences M&A. It signals continued investment in drug development infrastructure, impacting regulatory and transactional advisory work.
- THL Partners will buy Celerion for $1.8 billion, marking a major healthcare private equity move.
- Celerion specializes in early clinical research and bioanalytical sciences, supporting leading pharma firms.
- THL's latest fund raised $6.35 billion with a 92% investor re-up rate, bolstering its capacity for deals.
- The transaction is set to close in 2026, subject to customary closing conditions.
Boston-based private equity firm THL Partners will acquire a controlling interest in Nebraska's Celerion, a clinical pharmacology and bioanalytical sciences company, for $1.8 billion. The transaction, announced this week, continues 2026's trend of sizable private equity bets on healthcare research providers.
- Celerion was previously acquired by H.I.G. Capital in November 2022, illustrating rapid deal cycles and strong market appetite.
- "Celerion has built a reputation as a trusted partner to leading pharmaceutical and biotechnology companies, grounded in scientific rigor, operational excellence, and a deep commitment to advancing patient outcomes," said Dr. Susan Thornton, Celerion's CEO.
- The acquisition aligns with THL's aggressive healthcare investing, following the close of its $6.35 billion Fund X, which boasted a 92% re-up rate among existing investors.
- Celerion is a critical partner for pharma and biotech innovation, especially in early clinical phases, said Megan Preiner, Managing Director at THL.
The deal is expected to finalize in 2026 after regulatory clearance and customary closing conditions. Legal teams advising on M&A in the healthcare and life sciences space will be watching closely as the transaction demonstrates ongoing investor confidence and reveals potential for further consolidation.
By the numbers:
- $1.8 billion — Value of the Celerion acquisition by THL Partners
- 12x — Approximate EBITDA multiple for the deal
- $6.35 billion — Funds raised by THL Partners for its 10th flagship fund
Yes, but: Details on post-acquisition strategy and specific operational changes for Celerion remain undisclosed.
What's next: The acquisition is expected to close in 2026 pending regulatory approval and standard closing conditions.